Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study
- PMID: 27997989
- DOI: 10.1002/hep.28992
Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study
Abstract
Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing portal pressure. Whether weight reduction can be safely achieved through lifestyle (LS) changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown. This prospective, multicentric, uncontrolled pilot study enrolled patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [HVPG] ≥6 mm Hg), and body mass index (BMI) ≥26 kg/m2 in an intensive 16-week LS intervention program (personalized hypocaloric normoproteic diet and 60 min/wk of supervised physical activity). We measured HVPG, body weight (BW) and composition, adipokines, health-related quality of life, and safety data before and after the intervention. Changes in HVPG and BW were predefined as clinically relevant if ≥10% and ≥5%, respectively. Safety and BW were reassessed after 6 months. 60 patients were included and 50 completed the study (56 ± 8 years old; 62% male; nonalcoholic steatohepatitis etiology 24%; BMI 33.3 ± 3.2 kg/m2 ; Child A 92%; HVPG ≥10 mm Hg, 72%). LS intervention significantly decreased BW (average, -5.0 ± 4.0 kg; P < 0.0001), by ≥5% in 52% and ≥10% in 16%. HVPG also significantly decreased (from 13.9 ± 5.6 to 12.3 ± 5.2 mm Hg; P < 0.0001), by ≥10% in 42% and ≥20% in 24%. A ≥10% BW loss was associated with a greater decrease in HVPG (-23.7 ± 19.9% vs. -8.2 ± 16.6%; P = 0.024). No episodes of clinical decompensation occurred. Weight loss achieved at 16 weeks was maintained at 6 months; Child and Model for End-Stage Liver Disease scores did not change.
Conclusion: Sixteen weeks of diet and moderate exercise were safe and reduced BW and portal pressure in overweight/obese patients with cirrhosis and portal hypertension. (Hepatology 2017;65:1293-1305).
Trial registration: ClinicalTrials.gov NCT01409356.
© 2016 by the American Association for the Study of Liver Diseases.
Comment in
-
Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis.Hepatology. 2018 Apr;67(4):1644-1645. doi: 10.1002/hep.29801. Epub 2018 Feb 28. Hepatology. 2018. PMID: 29357107 No abstract available.
-
Reply.Hepatology. 2018 Apr;67(4):1645-1646. doi: 10.1002/hep.29799. Hepatology. 2018. PMID: 29357191 No abstract available.
Similar articles
-
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.Gastroenterology. 2007 Aug;133(2):481-8. doi: 10.1053/j.gastro.2007.05.024. Epub 2007 May 21. Gastroenterology. 2007. PMID: 17681169 Clinical Trial.
-
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.J Viral Hepat. 2017 Oct;24(10):823-831. doi: 10.1111/jvh.12706. Epub 2017 Apr 10. J Viral Hepat. 2017. PMID: 28295923
-
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.J Hepatol. 2020 May;72(5):885-895. doi: 10.1016/j.jhep.2019.12.010. Epub 2019 Dec 21. J Hepatol. 2020. PMID: 31870950 Clinical Trial.
-
The portal hypertension syndrome: etiology, classification, relevance, and animal models.Hepatol Int. 2018 Feb;12(Suppl 1):1-10. doi: 10.1007/s12072-017-9827-9. Epub 2017 Oct 24. Hepatol Int. 2018. PMID: 29064029 Review.
-
Offspring body size and metabolic profile - effects of lifestyle intervention in obese pregnant women.Dan Med J. 2014 Jul;61(7):B4893. Dan Med J. 2014. PMID: 25123127 Review.
Cited by
-
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1. Hepatol Int. 2020. PMID: 33006093
-
Impact of Liver and Pancreas Diseases on Nutritional Status.Nutrients. 2021 May 13;13(5):1650. doi: 10.3390/nu13051650. Nutrients. 2021. PMID: 34068295 Free PMC article. Review.
-
Management and Risks Before, During, and After Liver Transplant in Individuals With Obesity.Gastroenterol Hepatol (N Y). 2023 Jan;19(1):20-29. Gastroenterol Hepatol (N Y). 2023. PMID: 36865816 Free PMC article.
-
Sarcopenia in Liver Transplantation.Curr Transplant Rep. 2019 Mar;6(1):7-15. doi: 10.1007/s40472-019-0223-3. Epub 2019 Jan 21. Curr Transplant Rep. 2019. PMID: 31595213 Free PMC article.
-
Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes.PLoS One. 2023 Aug 24;18(8):e0290352. doi: 10.1371/journal.pone.0290352. eCollection 2023. PLoS One. 2023. PMID: 37616205 Free PMC article.
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical